'The Dermatological Drugs Market Will Reach $24.4 Billion in 2015' Shows Visiongain Report

LONDON, March 8, 2013 /PRNewswire/ --



A new report by visiongain predicts that the world market for dermatological drugs will reach $24.4 billion in 2015. That revenue forecast and others appear in Dermatological Drugs: World Market Prospects 2013-2023, published in March 2013. Visiongain is a business information provider based in London, UK.

Visiongain forecasts that the global dermatological drugs market will grow steadily from 2013 to 2023. That market is a high-revenue sector with a high public and healthcare profile. Revenue growth will be stimulated by an increase in disease prevalence, a result of aging populations and effects linked with modern life. Dermatological diseases often have high patient burden, resulting in significant disruption of everyday activities. Consumers continue to demand improved treatment options from healthcare providers.

Dr Peter Williamson, a pharmaceutical industry analyst in visiongain, said: "Growth in the market will be stimulated by new drugs and reformulations of existing products from 2013 onwards. The launch of treatments providing more efficacy, improved drug delivery, new dosing schedules and better-served patient populations will also drive market expansion. Visiongain believes that the psoriasis submarket will especially stimulate market growth. Biologic drugs, generating high revenue, will continue to dominate psoriasis treatments - a key element for market development. The emerging markets in India and China will also become important for dermatological medicines, driven by healthcare demand in those regions.

"The dermatologic drug market is broad, with scope for development in many areas. There is a high level of genericisation in acne and dermatitis markets. However, this will be countered through the launch of novel combination therapies. There will be opportunities in the infectious skin disease market, buoyed by increasing prevalence of skin and skin structure infections - a result of multidrug-resistant bacteria causing hospital and community acquired infections.

"In addition, a key issue facing physicians is patient adherence. For example, many topical psoriasis treatments are highly potent. However, treatment regimes can often be complicated and impractical for patients, leading to poor compliance and ultimately ineffective drugs. There are clear opportunities for drug developers to work closely with physicians and patients. These include the development of novel drug formulations and delivery technologies that are practical and patient friendly."

Visiongain's report shows revenue forecasts to 2023 at world market, therapeutic submarket, product and national level. It forecasts world sales for the following submarkets:

• Infectious skin disease
• Psoriasis
• Dermatitis
• Acne
• Other treatments.

That investigation also forecasts sales of 23 leading and recently launched drugs, including Cubicin, Zyvox, Humira, Enbrel, Stelara, Claravis, Epiduo and Protopic.

The analysis includes researching trends and forecasting revenues in leading national markets. Countries and regions analysed are the US, Japan, EU5 (Germany, the UK, France, Italy and Spain), China, India, Brazil and Russia (BRIC).

Dermatological Drugs: World Market Prospects 2013-2023 adds to visiongain's range of analytical reports on industries and markets in healthcare.

For sample pages and further information concerning the visiongain report Dermatological Drugs: World Market Prospects 2013-2023, please visit: http://www.visiongain.com/Report/993/Dermatological-Drugs-World-Market-Prospects-2013-2023

For an executive summary please contact:
Email: Sara Peerun on sara.peerun@visiongainglobal.com
Tel: +44-(0)20-7336-6100

Companies Listed

3SBio
Abbott Laboratories
Actavis
Affiinium
AiCuris
Allergan
Almirall
Amgen
Anacor Pharmaceuticals
AndroScience Corp
Anterios
ApoPharma
Apote
Apotex
Apotheca
Applied Genetics
Astellas Pharma
Astion
AstraZeneca
Asubio Pharma
Aurobindo Pharma
Ausio Pharmaceuticals
Basilea Pharmaceutica
Bayer
BergPharma
BioCryst Pharmaceuticals
Biofrontera Bioscience
Biofrontera Pharma GmbH
BioMAS
Biotest
Biovail
Birken
Braintree Laboratories
Bristol-Myers Squibb
British Association of Dermatologists
California Institute of Technology
Can-Fite BioPharma
Causa Research
Celgene Corporation
Cempra
Centocor Ortho Biotech
Cipher Pharma
Cipla
CollaGenex Pharmaceuticals
Cosmo Pharmaceuticals
Cubist Pharmaceuticals
Cutanea Life Sciences
Daiichi Sankyo
DAVA Pharmaceuticals
Dermik
Dermira
Dr. Reddy's Laboratories
Durata Therapeutics
DUSA Pharmaceuticals
Eisai
Eli Lilly
European Medicines Agency (EMA)
Foamix
Forest Laboratories
Forward-Pharma GmbH
Fougera
French Medicines Agency
Furiex Pharmaceuticals
G&E Herbal Biotechnology Co
G&W Labs
Galderma
Gene Signal International
Genzyme
GlaxoSmithKline (GSK)
Glenmark Pharmaceuticals
Graceway Pharmaceuticals
Gruenenthal
Hanwha Pharma
Health Canada
Heritage Pharmaceuticals
Immunex
Impax Pharmaceuticals
Incyte
Innovaderm Research
iNova Pharmaceuticals
Intercell
Intrepid Therapeutics
Isotechnika Pharma
Janssen
Janssen Biotech
Johnson & Johnson
KV Pharmaceuticals
LEO Pharma
Ligand Pharmaceuticals
Lupin Pharmaceuticals
Lux Biosciences
Maruho Co
Massachusetts General Hospital
Matrix Laboratories
Meda AB
Medici
Medicines and Healthcare Products Regulatory Agency (MHRA)
Medicis
Medimetriks Pharmaceuticals
Merck & Co.
Merz Pharmaceuticals
Mitsubishi Tanabe Pharma
Mochida Pharmaceutical Co
Morria Biopharmaceuticals
Mycenax Biotech
Mylan Pharmaceuticals
Nabriva Therapeutics
NanoBio Corporation
National Cancer Institute
National Institutes for Health (NIH)
NovaDigm Therapeutics
Novartis
Nycomed
Oplon-Pure Science
Par Pharmaceuticals
Paratek Pharmaceuticals
Perrigo
Pfizer
Photocure
Pierre Fabre Medicament
Pliva Hrvatska
PolyMedix
Promius Pharma
Provectus Pharmaceuticals
QuatRx Pharmaceuticals
Ranbaxy Pharmaceuticals
Rib-X Pharmaceuticals
Roche
Roxane Laboratories
Sandoz
Sanofi
Sanofi-Pasteur
Schering-Plough
Shinogi
Sol-gel Technologies
Star Pharma
Stiefel Laboratories
Takeda Pharmaceuticals
Targanta Therapeutics
Taro Pharmaceutical Industries
Teva Pharmaceutical Industries
The American Academy of Dermatology
The Brazilian Society of Dermatology
The Medicines Company
Theravance
Tolmar
Topica Pharmaceuticals
Trius Therapeutics
UCB
University of Cologne
US Department of Health and Human Services
US Food and Drug Administration (FDA)
Valeant Pharmaceuticals
Wake Forest University School of Medicine
Warner Chilcott
Watson Laboratories
Welichem Biotech
Wyeth
Xoma
Zalicus
Zurita Laboratorio Farmaceutico

About visiongain

Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-2-business conferences, newsletters, management reports and e-zines focusing on the Energy, Telecoms, Pharmaceutical, Defence, Materials and Automotive sectors.
Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port-of-call for the business professional, who needs independent, high quality, original material to rely and depend on.

Notes for Editors

If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44-(0)207-336-6100